Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11,930.00
Bid: 11,936.00
Ask: 11,940.00
Change: -98.00 (-0.81%)
Spread: 4.00 (0.034%)
Open: 12,052.00
High: 12,094.00
Low: 11,880.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: US-China Trade Talk Optimism Sends Miners Higher

Fri, 29th Mar 2019 12:30

LONDON (Alliance News) - London share prices were higher at midday Friday, with the FTSE 100 lifted by mining stocks amid optimism over US-China trade talks and despite significant hits to blue-chip shares TUI and AstraZeneca.The FTSE 100 index was up 0.4%, or 26.45 points, at 7,260.78. The FTSE 250 was up 0.5%, or 93.06 points, at 19,001.65, and the AIM All-Share up 0.4% at 914.58.The Cboe UK 100 was up 0.4% at 12,320.95, the Cboe UK 250 up 0.4% at 17,036.26, and the Cboe Small Companies up 0.1% at 11,162.63. In Paris the CAC 40 was up 0.8%, while the DAX 30 in Frankfurt was up 0.9%. "Shanghai's SSE Composite index jumped 3.2% on hopes that the US and China were making progress with trade talks. This optimism also gave a boost to the London-listed natural resources sector with mining shares topping the list of FTSE 100 risers," commented Russ Mould, investment director at AJ Bell.Antofagasta, Glencore, Anglo American, Rio Tinto and BHP Group shares were up 2.6%, 2.3%, 2.0%, 1.8% and 1.8% respectively, with these shares making up most of the top-five large-cap gainers for the majority of the morning Friday."Miners were among the main beneficiaries of the trade talks as they depend on the re-establishment of tariff-free trade flows in and out of China. Glencore, Rio Tinto and other miners have gained close to 2% this morning, leading the FTSE risers' table and Rio Tinto managed to avoid being knocked down for declaring force majeure on some of its iron ore contracts," said CityIndex senior market analyst Fiona Cincotta.The pound was quoted at USD1.3099 at midday, firm compared to USD1.3044 the London equities close Thursday. However, the pound has seen little volatility Friday despite investors bracing for another vote in parliament on a stripped-down version of UK Prime Minister Theresa May's twice-defeated UK divorce deal this afternoon around 1430 GMT.The PM's decision to present just the Withdrawal Agreement portion of her deal to the Commons means it is not a third attempt to pass a "meaningful vote" on the total deal and complies with rules laid down by Commons Speaker John Bercow.However, May faces a significant struggle as key government allies the DUP have joined Labour leader Jeremy Corbyn in saying that they will vote against the move due to concerns about a trade border being eventually imposed between Northern Ireland and the rest of the UK."It may be surprising therefore to see that the pound has turned south this week but hasn't broken any major levels, just moved back to the lower end of its recent range, so traders aren't too gloomy. The reason for this is simple, no-deal remains possible but unlikely," commented Oanda senior market analyst Craig Erlam.The annual figure for UK gross domestic product growth received a slight bump Friday, data from the Office for National Statistics showed, revised up to 1.4% from 1.3% reported prior. Despite small upgrade, economic growth in 2018 was the slowest pace since 2012 and was down from 2017's growth of 1.8%."UK quarterly GDP was confirmed at 0.2% for the final three months of 2018, the joint lowest level since 2013. Meanwhile, while many will cheer the growth upgrade from the ONS which saw an annual figure of 1.3% raised to 1.4%, this represents the lowest level of growth since 2012. Interestingly, we saw a 'large net inflow of portfolio investment into the UK', which certainly runs contrary to the perception that money is flooding out of the country ahead of Brexit," said Joshua Mahony, senior market analyst at IG.The FTSE 100 had some significant losers at midday for company-specific reasons. TUI shares dropped 6.7% after the Anglo-German travel company warned that the grounding of the Boeing 737 Max aircraft will hit annual earnings and will result in a large exceptional charge. Boeing 737 Max aircrafts have been grounded by countries around the world following two fatal crashes in the past five months. Assuming resumption of 737 Max flights by mid-July, TUI is estimating a one-off charge of EUR200 million on adjusted earnings before interest, taxes and amortisation for its financial year to the end of September. As a result of the exceptional charge, TUI expects underlying Ebitda for 2019 financial to fall by 17%, versus previous broadly flat guidance.If the plane is not flying by mid-July, the annual hit will be even larger, TUI warned.AstraZeneca dropped 6.1% after announcing it plans an up to USD6.9 billion collaboration agreement with Japan's Daiichi Sankyo. A USD3.5 billion equity fund raise will be conducted by Astra to help pay for this. Under the agreement, which covers potential cancer treatment trastuzumab deruxtecan, Astra will make an upfront USD1.35 billion payment to Daiichi Sankyo, followed by contingent payments of as much as USD5.55 billion for a total of up to USD6.90 billion. Of the USD5.55 billion contingent payments, USD3.80 billion will be paid out to the Japanese company for regulatory milestones and USD1.75 billion will be for sales-related milestones.Micro Focus shares were down 0.4% after saying that it expects a moderation in the decline of its revenue for the continuing business.In its annual general meeting statement, the FTSE 100 enterprise software company said it continued to expect a revenue decline between 4% and 6% for the financial year to October, slower than the 7.1% drop suffered a year ago. Man Group shares rose 4.0% after Credit Suisse initiated the hedge fund manager with an Outperform rating. Meanwhile, an upgrade to Neutral from Sell by UBS lifted Jupiter Fund Management 3.1%Stocks in New York were set for higher open with major stock indices pointed up 0.4%. By Idris Nur; idrisnur@alliancenews.com

More News
12 Apr 2024 12:55

EU regulator rules out link between weight-loss drugs and suicidal thoughts

April 12 (Reuters) - The European Union drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo Nordisk's hugely popular Wegovy, are linked to suicidal thoughts, it said on Friday, ending a nine-month probe.

Read more
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.